Shots:

• HitGen to receive upfront & milestones from Almirall to develop novel small molecules for Almirall’s target
• The focus of the collaboration is to utilize HitGen’s technology based on DNA-encoded library design- synthesis and screening- in identifying small molecules for the treatment of atopic dermatitis
• HitGen’s DELs is a drug discovery platform including 400B macrocyclic compounds developing biological targets. The company has also collaborated with other companies & foundations in North America- Europe- Asia & Africa to discover therapies & agrochemical solutions in multiple therapy areas

Click here to read full press release/ article | Ref: HitGen | Image: Business Wire